NCT01752894View on ClinicalTrials.gov

DETErmination of the Duration of the Dual Antiplatelet Therapy by the Degree of the Coverage of The Struts on Optical Coherence Tomography From the Randomized Comparison Between Everolimus-eluting Stents(EES) Versus Biolimus A9-eluting Stents(BES)

NACompletedINTERVENTIONAL
Enrollment

776

Participants

Timeline

Start Date

January 2, 2013

Primary Completion Date

April 11, 2017

Study Completion Date

April 11, 2017

Conditions
Ischemic Heart Disease
Interventions
DEVICE

Angio-guided PCI with EES or BES

Angio-guided intervention

DEVICE

OCT-guided PCI with EES or BES

OCT-guided intervention

DEVICE

PCI with BES under angio-guide or OCT guide

biolimus A9-eluting stent.

DEVICE

PCI with EES under angio-guide or OCT guide

everolimus eluting stent.

DRUG

Keep DAPT

maintain DAPT for 12 months according to level of uncovered strut (\>6%) at 3months OCT follow up after stent implantation.

DRUG

Discontinue DAPT

discontinue DAPT according to level of uncovered strut (≤6%) at 3months OCT follow up after stent implantation.

Trial Locations (1)

120-752

Division of Cardiology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul

All Listed Sponsors
lead

Yonsei University

OTHER

NCT01752894 - DETErmination of the Duration of the Dual Antiplatelet Therapy by the Degree of the Coverage of The Struts on Optical Coherence Tomography From the Randomized Comparison Between Everolimus-eluting Stents(EES) Versus Biolimus A9-eluting Stents(BES) | Biotech Hunter | Biotech Hunter